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level simulation considering a cohort of 1.000.000 individuals of 60 years of age 
in a time horizon of 5 years, assuming a retirement age of 65. PCV effectiveness 
was extrapolated from infant results. Absence days due to health events were 
retrieved from national labor legislations. Average wage was retrieved from the 
Brazilian Institute for Geography and Statistics (IBGE) 2012 data and productivity 
was estimated from the indicator ‘revenue generated by the employee’, from a 
market research developed by Exame magazine in 2012 using IBGE and the 
Brazilian Central Bank data. The base case considered a large corporation in 
Brazil with approximately 4000 eligible individuals. Values were expressed in 
2012 USD. RESULTS: Independent campaign with PPV23 and PCV13 vaccination 
plus free campaign totaled US$40.62 and US$61.40 per employee respectively. 
Productivity loss due to sick leave and death was US$709.61 and US$640.80 for 
PPV23 and PCV13 per employee, respectively. Considering all evaluated costs per 
employee and the number of eligible individuals, PPV23 and PCV13 totaled 
US$3,000,901.79 and US$2.808.787,58, respectively, representing US$192,114.21 of 
total savings for PCV13 vaccination when compared to PPV23. CONCLUSIONS: 
PCV13 vaccination with free campaign is estimated to save costs to employers, 
when compared to developing an independent campaign, mainly driven by 
productivity loss due to sick leave and death, which represented 112,07% of the 
total investment in a time horizon of 5 years.  
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OBJECTIVES: HAV is the most common cause of viral hepatitis in Latin America. 
We aimed to assess the cost-effectiveness of universal HAV immunization in 
Mexico. METHODS: A published dynamic transmission model was used to 
project the annual frequency of symptomatic HAV infections (sHAV) for a 25-
years timeframe. A decision tree allowed estimating the health and economic 
burden associated with sHAV for either a one-dose or a two-dose scheme in 
toddlers as well as without vaccination. A 80% vaccine coverage was used by 
weighting the data reported for 70% and 90% scenarios. Analysis was conducted 
from the perspective of the public health care institutions. Direct medical costs 
comprising both acquisition and administration of HAV vaccine besides medical 
care of sHAV cases were assessed. Costs are expressed in 2012 Mexican pesos 
(MXN). An average disutility value of 0.019 was imputed to each sHAV case. 
Exhaustive sensitivity analyses were performed. RESULTS: Without vaccination 
15,178,489 sHAV are expected for the period 2012-2036. Direct medical costs of 
$10,447 million MXN will be imposed by these cases, which will also entail a loss 
of 242,943 quality-adjusted life years (QALY). The one-dose scheme led to 36% 
and 32% reductions in the frequency of sHAV and QALY lost respectively, 
whereas for the two-dose scheme these reductions were of 54% and 45%. 
Incremental cost-utility ratios of $22,079 and $42,843 MXN were calculated for 
one-dose and two-dose schemes, respectively. The cost per additional QALY 
gained with two-dose versus one-dose scheme was $94,557 MXN. All these 
figures are less than the GDP per capita in Mexico ($136,384 MXN). Model was 
robust; one-dose and two-dose schemes were preferred in 42 and 57% of the 
second-order Monte-Carlo simulations. CONCLUSIONS: These results suggest 
that universal vaccination of toddlers against HAV in Mexico (either with a 1-
dose or a 2-doses scheme) is a highly cost-effective intervention.  
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OBJECTIVES: External ventricular drain (EVD) catheters provide standard means 
of monitoring intracranial pressure and alleviating excess cerebrospinal fluid 
(CSF). Up to 27% of patients with EVD catheters develop an infection. Antibiotic-
impregnated catheters (AICs) were used to reduce EVD catheter-related 
infections and the associated complications. The study was conducted to 
determine whether adopting AICs as a strategy to reduce EVD catheter-related 
infections in Canadian hospitals would be cost-effective. METHODS: Clinical and 
economic data was obtained from peer-reviewed literature along with case-
costing data from a large Canadian hospital. One and two way sensitivity 
analyses were conducted on clinical and economic parameters to ensure 
robustness. The model outcomes reflect that of a hospital with 250 catheter 
insertions per year. The data used to demonstrate a reduction in infection rate 
resulting from the use of AICs comes from a prospective, randomized, controlled 
trial. The cost of treating one episode of infection was calculated by using 
associated additional length of stay and its cost. Information regarding the cost 
was obtained from a large Canadian hospital. RESULTS: Adopting AICs as EVD 
catheters could reduce the incidence of catheter-related infection from 9.4% to 
1.3%. Using a hypothetical hospital that completes a total of 250 EVD catheter 
insertions per year would experience 24 infections using conventional catheters. 
Adopting AICs would reduce the number of infections to 4, for a total reduction 
of 20 infections. Patients that acquire infection during EVD catheter insertion 
spend an average of 8.5 additional days in hospital. The model establishes that 
the use of AICs has the potential to provide the hospital with a yearly net cost 
savings of $250,599 despite the added costs of AICs. CONCLUSIONS: AICs are a 
cost-effective strategy that can be used to prevent catheter-related CSF infection 
for EVD catheter insertion in Canadian hospitals.  
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OBJECTIVES: Current U.S. Department of Health and Human Services (DHHS) 
HIV treatment guidelines recommend that HIV patients initiate first-line 
antiretroviral therapy (ART) with one of four “preferred” regimens: 
efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC), ritonavir-boosted atazanavir + 
tenofovir/emtricitabine (ATV/r+TDF/FTC), ritonavir-boosted darunavir + 
tenofovir/emtricitabine (DRV/r+TDF/FTC), or raltegravir + tenofovir/emtricitabine 
(RAL+TDF/FTC). While the clinical value of these regimens is well-supported, 
there are limited data on their relative economic value. This study compared 
health care expenditures between the four “preferred” ART regimens. METHODS: 
Retrospective study using Medicaid administrative health care claims from 15 
states. Subjects were HIV patients aged 18-64 years who were enrolled in 
Medicaid and initiated, between January 1, 2007 and September 30, 2011, a first-
line ART regimen “preferred” under U.S. DHHS HIV treatment guidelines 
published in March 2012. Patients were classified by ART regimen and were 
required to be continuously enrolled for 6 months before and ≥3 months 
following ART initiation. Follow up lasted from ART initiation until a ≥30 day gap 
in initiated ART, introduction of a new ART medication, or disenrollment. Per-
patient-per-month (PPPM) total mean health care expenditures during follow up 
were evaluated using log-linear regressions. Log-expenditures were 
retransformed via ‘smearing.’ Inference was based on recycled prediction with 
500 bootstrap repetitions. RESULTS: Sample included 1,979 patients initiating 
EFV/TDF/FTC (n=1,259), ATV/r+TDF/FTC (n=498), DRV/r+TDF/FTC (n=143), or 
RAL+TDF/FTC (n=79); mean age by regimen ranged from 40.1 to 42.1 years and 
proportion male from 44.1% to 55.4%. PPPM total mean health care expenditures 
for EFV/TDF/FTC patients were $3,476. In comparison, PPPM total mean health 
care expenditures were significantly higher for DRV/r+TDF/FTC patients (by 
$2,155, 95% CI =$1,364 to $3,074, p<0.01), ATV/r+TDF/FTC patients (by $1,379, 95% 
CI=$951 to $1,971, p<0.01) and RAL+TDF/FTC patients (by $1,479, 95% CI=$544 to -
$2,526, p<0.01) than for EFV/TDF/FTC patients. CONCLUSIONS: This study found 
significant differences in health care expenditures between HIV patients 
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OBJECTIVES: Shunts provide standard means of monitoring intracranial pressure 
and alleviating raised cerebrospinal fluid (CSF). Up to 15% of patients with shunts 
develop an infection. Antibiotic-impregnated catheters (AICs) were used with the 
goal to reduce shunt-related CSF infections and the associated complications. 
The study was conducted to determine whether adopting AICs as a strategy to 
reduce shunt infections in Canadian hospitals would be cost-effective. 
METHODS: Clinical and economic data was obtained from peer-reviewed 
literature along with case-costing data from a large Canadian hospital. One and 
two way sensitivity analyses were conducted on clinical and economic 
parameters. The model outcomes reflect that of a hospital with 250 shunt 
implantations per year. The clinical data used to demonstrate a reduction in 
shunt infections resulting from the use of AICs comes from a 2011 meta-analysis 
(Klimo et al., 2011) as well as from the outcomes of the Canadian Nosocomial 
Infection Surveillance Program. Information regarding the cost of treating an 
infected patient was obtained from a large Canadian hospital. RESULTS: 
Adopting AICs in shunt implantations could result in a relative risk reduction of 
50% in shunt-related CSF infections. Using a hypothetical hospital that 
completes a total of 250 shunt implantations per year would experience 16 shunt 
infections using conventional catheters. Adopting AICs would reduce the 
number of infections to 8, for a total reduction of 8 shunt infections. The model 
establishes that the use of AICs has the potential to provide the hospital with a 
yearly net cost savings. Taking into account the catheter replacement costs 
associated with shunt infections, the hospital would still achieve a cost savings 
of $509,632 per year despite the added upfront costs of AICs. CONCLUSIONS: 
AICs are a cost-effective strategy that can be used to prevent shunt-related CSF 
infection after shunt implantation in Canadian hospitals.  
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OBJECTIVES: To examine whether the average direct medical costs paid for adult 
vaccination differed by the vaccination setting. METHODS: An observational 
retrospective study using 2010 MarketScan® Commercial Claims and Encounters, 
and Medicare Supplemental databases. Adults receiving ZOSTAVAX® (herpes 
zoster or shingles vaccine), PNEUMOVAX® 23 (pneumococcal vaccine), or 
influenza vaccines were identified using CPT and NDC codes from medical and 
pharmacy claims files, respectively. The vaccination costs included the health 
plan and enrollee paid amounts for the product, vaccine administration, and 
where applicable, the visit. The mean (SD) vaccination costs paid per vaccine 
A86 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
administration were examined by vaccine and type of setting including 
physician offices, pharmacies, and other medical settings (e.g., 
inpatient/outpatient hospitals, emergency rooms). RESULTS: Of those receiving 
ZOSTAVAX®, PNEUMOVAX® 23 and influenza vaccines, 25%, 1%, and 7%, 
respectively, received it at a pharmacy. Compared to other US regions, 
pharmacy-based vaccination for these 3 vaccines was generally higher in the 
western and southern regions. Overall, the mean (SD) paid amounts per enrollee 
per vaccine administration at the physician offices, pharmacies, and other 
medical settings were as follows: ZOSTAVAX® $208.7 (42.1), $168.5 (15.7), and 
$209.5 (50.8), respectively (p<0.05); PNEUMOVAX® 23 $65.6 (27.5), $55.0 (9.7), and 
$72.1 (50.0), respectively (p<0.05); and influenza $29.3 (15.3), $21.6 (6.6), and $24.2 
(13.1), respectively (p<0.05). The mean paid amounts also differed by geographic 
regions and type of health plan, with costs usually lower for the vaccinations 
given at the pharmacies. CONCLUSIONS: The average direct costs per adult 
vaccination were lower in pharmacies, compared to physician offices and other 
medical settings by 16-26% and 11-20 %, respectively. These results were mostly 
consistent across geographic regions and types of health plans. These data may 
help payer and policymaker understand economic value of adult vaccination in 
different settings, especially in pharmacies.  
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OBJECTIVES: Currently, diagnosis of a bloodstream infection relies on culture-
based methods and takes 2-3 days. The development of a rapid diagnostic tool 
has been deemed a high priority by the Infectious Disease Society of America. 
Available rapid tests are limited by the need to target specific pathogens. Rapid 
tests for universal detection of bacterial or fungal pathogens are in development. 
Commercialization of such a test will allow physicians to make rapid decisions, 
avoid unnecessary hospitalization, and decrease morbidity. No economic 
analyses have yet assessed the potential medical cost impacts of such a test. 
METHODS: We performed a decision tree analysis to estimate the potential 
medical cost consequences of a rapid test to detect bloodstream infection, using 
data from published literature and expert opinion. We considered potential 
impacts in the areas of diagnostic testing, prevention of diseases, and reduction 
in hospital admissions. Medicare pricing schedules were used, analyses were 
conducted from the health care payer perspective, and a base case cost of 
$20/test was used. RESULTS: Our model demonstrates that with population-wide 
implementation, the annual U.S. medical cost savings associated with decreased 
clinical diagnostic testing, reduced antimicrobial use, disease prevention, 
avoidance of hospitalization, and reduction in hospital length of stay could be 
$0.2, $0.3, $1.2, $1.1 and $1.6 billion, respectively. An increase in diagnostic 
testing cost to $40, $50 and $60/test lowers net savings by 3.6%, 5.4% and 7.2%, 
respectively. A tripling of the testing cost still allows for net savings of >$3.6 
billion to the health care system. CONCLUSIONS: Our analysis suggests that 
routine hospital-based use of a rapid diagnostic test for bacterial and fungal 
bloodstream infections would result in substantial savings to U.S. health care 
payers. If such a test were available, and its negative predictive value for 
bloodstream infection were very high, it would likely become a dominant 
diagnostic strategy.  
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OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C 
(HCV) in Germany (62% genotype 1). HCV is one of the leading causes for chronic 
liver disease. Experts have estimated that about 27% of end-stage cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. Although HCV is 
associated with high costs, reliable data are scarce in Germany. Aim of the study 
was to assess the costs for treating chronically infected HCV patients in routine 
care. METHODS: We conducted a retrospective multicenter observational study. 
Design was approved by an ethics committee and patients were asked for their 
informed consent. Health care utilization was extracted from doctor files in six 
medical centers. Costs were calculated using official fee-scales and statistics. 
Societal perspective was taken. RESULTS: In total, 315 patients were analyzed. 
The mean age was 49.4 years, 57.5% were male and 67.9% had a genotype-1 
infection. Most common routes of transmission were injection drug use (39.0%) 
and infection through blood products (15.9%). In 41.3% of patients route of 
transmission was unknown. The average total costs were €19,147 including 
ambulatory care (€1,686), pharmaceuticals (€14,875), inpatient care (€1,293) and 
sick leave (€1,293). Cost differences were observed between patients groups (mild 
HCV, moderate HCV and compensated cirrhosis, decompensated cirrhosis). 
Patients receiving a 16-week treatment had average total costs of €8,230. A 24-
week treatment resulted in €13,674, 48-week treatment in €25,396 and 72-week 
treatment in €41,175. In nearly 30% of patients treatment duration did not 
correspond to official recommendations. CONCLUSIONS: Treatment of HCV 
patients is associated with high costs mainly affected by length of antiviral 
therapy. It is inevitable to follow current guidelines and monitor patients closely 
in order to avoid unnecessary costs. The analysis is the basis for implementing 
new therapies which started with the introduction of protease inhibitors in 2011.  
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OBJECTIVES: To determine the economic and health care resource burden of 
seasonal Influenza, in the UK, using linked, individual patient, hospital and 
family doctor records, including mortality stratified by; age, risk factors and 
complications. METHODS: A cross-sectional observational study design was 
carried out using data derived from linked GPRD, between January 2001 and 
March 2009. Subjects included were; all those with family doctor coded episodes 
of care for acute respiratory events related to infection (influenza, upper and 
lower respiratory tract infections (LRTI), and Influenza like illness (ILI)). Analysis 
was stratified by age and ‘at risk’ conditions recommended for influenza 
vaccination in the UK. UK 2011 published reference costs were used. RESULTS: 
156,193 influenza episodes were recorded during the study period, with mean 
age 42.7 years (SD 20.3). Of these 1,592 (1.0%) were hospitalised with mean length 
of stay of 7 days; 1,182 (0.8%) deaths occurred within 28 days. The risk of 
hospitalisation and mortality was lower in those vaccinated; odds ratio 0.59 and 
0.78 respectively. Cardiovascular complications, COPD and LRTI were associated 
with the largest number of deaths. Highest mortality rates were in patients 
≥65yrs. Costs escalate with complicated influenza episodes (average cost 
influenza £2,264/hospitalisation vs. complicated influenza £9,384/hospitalisation) 
and age (≤64yrs £6,166/hospitalisation; ≥65yrs £11,674/hospitalisation). 
Respiratory and chronic heart disease risk status had highest overall costs, but 
CNS risk had highest cost per episode (£15,198/hospitalisation). CONCLUSIONS: 
This study, the first of its kind in the UK, demonstrates that seasonal influenza, 
even at a time of low overall activity, is associated with a substantial burden of 
illness, which is preventable by vaccination. This study is likely to underestimate 
the true impact of influenza due to; only capturing individuals who visit a 
physician, because most affected individuals self-diagnose, and the 
incompleteness and coding errors inherent within administrative databases.  
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OBJECTIVES: To evaluate health care utilization and costs of patients with 
aspergillosis within a large, commercially-insured population in the US. 
METHODS: Adults ≥18 years with at least one inpatient, emergency room, or 
outpatient medical claim with an aspergillosis diagnosis (ICD-9-CM 117.3 or 
484.6) between July 1, 2004 to March 1, 2011 and ≥6 months of pre-index and ≥1 
month of continuous post-index health plan and pharmacy benefit enrollment 
were identified from the MarketScan Research Databases. Patients with a diagnosis 
of aspergillosis in the pre-index period were excluded. Aspergillosis cases were 
propensity score-matched to a sample of controls without aspergillosis.. A 
general linear model was used to estimate total costs which were adjusted by 
the probability of remaining in the study to a given point in time (e.g., 90, 180, 
365 days). Incremental costs were calculated between cohorts and a bootstrap 
procedure was used to produce corresponding variation and 95% confidence 
interval estimates. RESULTS: Patients with aspergillosis (N= 5499; mean age: 57.8 
years; 48.6% female; 39.1% with cancer; 34% with an index diagnosis in the 
inpatient setting) were matched to 5499 controls (mean age: 58.3 years; 48.4% 
female; 40.3% with cancer). Aspergillosis cases had a higher proportion of 
hospitalizations and a longer average length of stay, as well as a higher rate of ER 
use and monthly outpatient office visits, laboratory tests, and outpatient 
prescriptions during follow-up than controls. All contrasts were significant at 
p<0.001. The estimated mean incremental costs of patients with aspergillosis, 
adjusted for the probability of remaining in the study for a given duration of 
follow-up time, were $22,732.99, $19,620.51 and $17,870.09 for durations of 90, 
180, and 365 days, respectively. CONCLUSIONS: The economic burden of 
aspergillosis is substantial. Patients with aspergillosis utilize significantly more 
health care and thus incur greater health care costs than do similar patients 
without aspergillosis.  
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OBJECTIVES: Low uptake of routinely recommended adult immunizations is a 
public health concern. Using data from peer-reviewed literature, we developed a 
customizable model to estimate the human and economic burden caused by four 
major adult vaccine-preventable diseases (VPD) in the United States and for each 
US state individually in 2010. METHODS: Three primary estimates were 
developed to populate the model: 1) estimated number of cases per year based 
on 2010 US Census population data and published incidence rates; 2) estimated 
direct medical costs of a single case; and 3) estimated indirect medical costs 
related to morbidity/lost productivity. Four major adult VPDs were examined: 1) 
influenza; 2) pneumococcal disease (both invasive disease and pneumonia); 3) 
herpes zoster; and 4) pertussis. RESULTS: Estimated US annual cost for the four 
adult VPDs was 15.1 billion (B) (10.4B for age ≥50). Among adults indicated for 
vaccination against the four VPDs, influenza (≥18yrs), pneumococcal disease 
